These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

500 related items for PubMed ID: 8923125

  • 21. Effectiveness of milnacipran for a patient with pain disorder and long QT syndrome.
    Ikawa M, Yamada K.
    Clin Neuropharmacol; 2010 May; 33(3):163-4. PubMed ID: 20173629
    [Abstract] [Full Text] [Related]

  • 22. SSRIS versus tricyclic antidepressants in depressed inpatients: a meta-analysis of efficacy and tolerability.
    Anderson IM.
    Depress Anxiety; 1998 May; 7 Suppl 1():11-7. PubMed ID: 9597346
    [Abstract] [Full Text] [Related]

  • 23. [Milnacipran and venlafaxine at flexible doses (up to 200 mg/d) in the outpatient treatment of adults with moderate-to-severe major depressive disorder: a 24-week randomised, double blind exploratory study].
    Olié JP, Gourion D, Montagne A, Rostin M, Poirier MF.
    Encephale; 2009 Dec; 35(6):595-604. PubMed ID: 20004291
    [Abstract] [Full Text] [Related]

  • 24. Milnacipran and pindolol: a randomized trial of reduction of antidepressant latency.
    Isaac MT, Isaac MB, Gallo F, Tournoux A.
    Hum Psychopharmacol; 2003 Dec; 18(8):595-601. PubMed ID: 14696018
    [Abstract] [Full Text] [Related]

  • 25. A meta-analysis of clinical trials comparing milnacipran, a serotonin--norepinephrine reuptake inhibitor, with a selective serotonin reuptake inhibitor for the treatment of major depressive disorder.
    Papakostas GI, Fava M.
    Eur Neuropsychopharmacol; 2007 Jan; 17(1):32-6. PubMed ID: 16762534
    [Abstract] [Full Text] [Related]

  • 26. Clinical utility of milnacipran in comparison with other antidepressants.
    Bisserbe JC.
    Int Clin Psychopharmacol; 2002 Jun; 17 Suppl 1():S43-50. PubMed ID: 12369610
    [Abstract] [Full Text] [Related]

  • 27. Levomilnacipran: a newly approved drug for treatment of major depressive disorder.
    Mago R, Mahajan R, Thase ME.
    Expert Rev Clin Pharmacol; 2014 Mar; 7(2):137-45. PubMed ID: 24524592
    [Abstract] [Full Text] [Related]

  • 28. Comparison of the cost-effectiveness of milnacipran (a SNRI) with TCAs and SSRIs: a modeling approach.
    Dardennes R, Berdeaux G, Lafuma A, Fagnani F.
    Eur Psychiatry; 1999 Jun; 14(3):152-62. PubMed ID: 10572341
    [Abstract] [Full Text] [Related]

  • 29. Problems with currently available antidepressants.
    Gumnick JF, Nemeroff CB.
    J Clin Psychiatry; 2000 Jun; 61 Suppl 10():5-15. PubMed ID: 10910012
    [Abstract] [Full Text] [Related]

  • 30. Prediction of antidepressant response to milnacipran by norepinephrine transporter gene polymorphisms.
    Yoshida K, Takahashi H, Higuchi H, Kamata M, Ito K, Sato K, Naito S, Shimizu T, Itoh K, Inoue K, Suzuki T, Nemeroff CB.
    Am J Psychiatry; 2004 Sep; 161(9):1575-80. PubMed ID: 15337646
    [Abstract] [Full Text] [Related]

  • 31. Effects of paroxetine or milnacipran on serum brain-derived neurotrophic factor in depressed patients.
    Yoshimura R, Mitoma M, Sugita A, Hori H, Okamoto T, Umene W, Ueda N, Nakamura J.
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jun 30; 31(5):1034-7. PubMed ID: 17459550
    [Abstract] [Full Text] [Related]

  • 32. Therapeutic effects of milnacipran (serotonin noradrenalin reuptake inhibitor) on depression following mild and moderate traumatic brain injury.
    Kanetani K, Kimura M, Endo S.
    J Nippon Med Sch; 2003 Aug 30; 70(4):313-20. PubMed ID: 12928711
    [Abstract] [Full Text] [Related]

  • 33. Milnacipran for fibromyalgia: a useful addition to the treatment armamentarium.
    Bernstein CD, Albrecht KL, Marcus DA.
    Expert Opin Pharmacother; 2013 May 30; 14(7):905-16. PubMed ID: 23506481
    [Abstract] [Full Text] [Related]

  • 34. Japanese experience with dual-action antidepressants.
    Tajima O.
    Int Clin Psychopharmacol; 2002 Jun 30; 17 Suppl 1():S37-42. PubMed ID: 12369609
    [Abstract] [Full Text] [Related]

  • 35. Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease.
    Roose SP, Laghrissi-Thode F, Kennedy JS, Nelson JC, Bigger JT, Pollock BG, Gaffney A, Narayan M, Finkel MS, McCafferty J, Gergel I.
    JAMA; 1998 Jan 28; 279(4):287-91. PubMed ID: 9450712
    [Abstract] [Full Text] [Related]

  • 36. Milnacipran for the treatment of chronic pain.
    Kamata M, Naito S, Takahashi H, Higuchi H.
    Hum Psychopharmacol; 2003 Oct 28; 18(7):575-6. PubMed ID: 14533142
    [No Abstract] [Full Text] [Related]

  • 37. Milnacipran. A review of its use in depression.
    Spencer CM, Wilde MI.
    Drugs; 1998 Sep 28; 56(3):405-27. PubMed ID: 9777315
    [Abstract] [Full Text] [Related]

  • 38. Pharmacotherapy for major depression with melancholic features: relative efficacy of tricyclic versus selective serotonin reuptake inhibitor antidepressants.
    Perry PJ.
    J Affect Disord; 1996 Jun 20; 39(1):1-6. PubMed ID: 8835647
    [Abstract] [Full Text] [Related]

  • 39. Efficacy and tolerability of moclobemide in comparison with placebo, tricyclic antidepressants, and selective serotonin reuptake inhibitors in elderly depressed patients: a clinical overview.
    Amrein R, Stabl M, Henauer S, Affolter E, Jonkanski I.
    Can J Psychiatry; 1997 Dec 20; 42(10):1043-50. PubMed ID: 9469236
    [Abstract] [Full Text] [Related]

  • 40. Selective serotonin reuptake inhibitors versus tricyclic antidepressants in young patients: a meta-analysis of efficacy and acceptability.
    Qin B, Zhang Y, Zhou X, Cheng P, Liu Y, Chen J, Fu Y, Luo Q, Xie P.
    Clin Ther; 2014 Jul 01; 36(7):1087-1095.e4. PubMed ID: 24998011
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 25.